Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 14/20 | 0.32 |
| ▸ | JAK3 | P52333 | 13/20 | 0.32 |
| ▸ | JAK2 | O60674 | 9/20 | 0.32 |
| ▸ | TYK2 | P29597 | 6/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001507 | 0.89 | JAK1 (0.34) | MEN1KMT2AMAPTJAK1JAK3 | |
| SCHEMBL22001733 | 0.86 | JAK2 (0.35) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL22001669 | 0.86 | MEN1 (0.32) | MEN1KMT2AMAPTJAK1JAK3 | |
| SCHEMBL22001729 | 0.86 | JAK1 (0.35) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL22001938 | 0.83 | JAK1 (0.45) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL22001612 | 0.83 | JAK1 (0.40) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL22001939 | 0.80 | JAK1 (0.41) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL24491095 | 0.78 | JAK1 (0.37) | MEN1KMT2AMAPTJAK1JAK3 | |
| SCHEMBL21448699 | 0.76 | JAK1 (0.41) | JAK1JAK3JAK2 | |
| SCHEMBL21387017 | 0.75 | MAPK1 (0.37) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | AVISTA PHARMA SOLUTIONS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200138811-A1 | Chemical Compounds | AVISTA PHARMA SOLUTIONS INC (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138811-A1 | Chemical Compounds | JAK1, JAK3, JAK2 | MEN1 4233/4885KMT2A 703/4885MAPT 1727/4885 |
| US-10744136-B2 | Sulfonamide derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | MEN1 4792/4885KMT2A 360/4885MAPT 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.